We investigated the schedule dependency of G-CSF (10 g/kg) alone in mobilizing peripheral blood progenitor cells (PBPC) in breast cancer patients. After a median of three cycles (range, 2-6) of anthracyclinebased chemotherapy, 49 patients with breast cancer (stage II/III, у10+ Ln n = 36; locally advanced/ inflammatory n = 8, stage IV (NED) n = 5) underwent PBPC collection after steady-state mobilization either with 1 × 10 g/kg (n = 27) or with 2 × 5 g/kg 
CD34
ϩ cells was achieved in 21/27 (80%) patients of the 1 × 10 g group and in 21/22 (95%) patients of the 2 × 5 g/kg group with a median of two aphereses (range, 1-4). None in the 10 g/kg group, but 6/22 (28%) patients in the 2 × 5 g/kg group required only one apheresis procedure, resulting in fewer apheresis procedures in the 2 × 5 g/kg group (mean, 1.8 vs 2.3, P = 0.01). These results demonstrate that priming with 10 g/kg G-CSF alone is well tolerated and effective in mobilizing sufficient numbers of CD34 ؉ cells in breast cancer patients and provide prompt engraftment after CTM high-dose chemotherapy. G-CSF given 5 g/kg twice daily (2 × 5 g) leads to a higher harvest of CD34 cells and required fewer apheresis procedures than when given 10 g/kg once daily (1 × 10 g). Keywords: stem cell mobilization; granulocyte colonystimulating factor; breast cancer High-dose chemotherapy followed by autologous stem cell rescue with peripheral blood progenitor cells (PBPC) is a widely used procedure to reconstitute durable hematopoiesis following myeloablative chemotherapy. [1] [2] [3] Infusion of mobilized peripheral blood stem cells results in a more rapid hematologic recovery than bone marrow alone. 2 PBSC can be mobilized by chemotherapy, 4 recombinant hematopoietic growth factors such as G-CSF or GM-CSF, [5] [6] [7] or a combination of both. [8] [9] [10] [11] The dose of PBPC infused, as measured by CD34
+ cell count, has been found to be an important predictor of engraftment, regardless of disease or technique of mobilization. 5, 12 Several studies have reported the influence of different chemotherapy regimens followed by growth factors on collection and engraftment of autologous PBPC. 9, 11 Data are limited regarding priming PBPC with G-CSF alone with a uniform breast cancer patient population. 13 Optimal dosing and scheduling remain to be determined. We have previously reported our dose-dependent experience with G-CSF-priming regarding the CD34 + cell count in patients with malignant lymphoma and testicular cancer.
14 The current retrospective study was undertaken to determine the effect and the schedule dependency on G-CSF-priming with 10 g/kg BW (1 × 10 g vs 2 × 5 g/kg daily) on CD34
+ cell yield and hematopoietic engraftment of PBSC in patients with breast cancer.
Patients and methods
In the present study, 49 women with high-risk breast cancer (stage II/III,10+ Ln n = 36; locally advanced/inflammatory n = 8, stage IV (NED) n = 5) were referred to our BMT unit for high-dose chemotherapy followed by PBSC infusion. All patients gave written informed consent for the administration of G-CSF, collection of peripheral blood stem cell and for high-dose chemotherapy. All protocols were approved by the local ethics committee.
All patients were required to have a WHO performance index Ͻ2 and adequate cardiac, renal, hepatic and hematological functions. . Patients with locally advanced disease/inflammatory carcinoma and stage IV disease received FAC or FEC chemotherapy. All but three patients with stage II/III disease and more than 10 involved lymph nodes received EC chemotherapy. Two patients with stage IV disease had received additionally three or six cycles of CMF chemotherapy. All patients received a median of three cycles (range, 2-6) at a 3-week interval. After complete hematological recovery the patients received 10 g/kg G-CSF (filgrastim; Amgen, Munich, Germany) daily subcutaneously. Since 1995, 22 patients received 5 g/kg twice daily with a time interval of 12 h. The results were compared with a historical group of 27 patients, who received 10 g/kg once daily in the morning. G-CSF administration was performed on an outpatient basis. Leukapheresis was started on day 5 usually 2-3 h after the last injection. G-CSF administration was continued until completion of leukapheresis. High-dose chemotherapy was given after the fourth cycle of induction chemotherapy and consisted in all patients of mitoxantrone (40 mg/m 2 ), thiotepa (600 mg/m 2 ) and cyclophosphamide (6000 mg/m 2 ) (CTM). The two groups were well balanced in terms of prior chemotherapy, age and stage of disease. For details of patient characteristics see Table 1 .
PBPC collection and cryopreservation
The collection of PBPC was performed identically in all patients with a Cobe Spectra (Cobe, Lakewood, CO, USA) using a 250 ml collection chamber. A total of 8 to 10 liters of blood per apheresis was processed at a flow rate of 50 to 70 ml/min; a mean volume of 250 ml was collected. This cell suspension was concentrated to a final volume of 50 ml Table 1 Effects of G-CSF stimulation with 1 × 10 g or 2 × 5 g/kg on progenitor cell dose, number of aphereses and hematological engraftment
Age: median (range) 42 years (27- and was mixed with 50 ml of minimal essential medium (MEM) containing 20% dimethylsulfoxide. The final 100 ml harvest product was transferred into freezing bags and frozen to −100°C with a computer controlled cryopreservation device. The frozen cells were transferred into liquid phase of nitrogen and stored at −196°C as described before. 15 
Progenitor cell assays
Unseparated MNC (1 × 10 5 /ml) were grown in a 1.25% methylcellulose solution containing 10% lymphocyte-conditioned medium, 10% human plasma, 20% fetal calf serum, 9% Iscove's media, and 2-mercaptoethanol. After a 14-day period of incubation in a humidified atmosphere of 5% CO 2 at 37°C, colony-forming units granulocyte-macrophage (CFU-GM) and CFU-E were counted using an inverted microscope as described before. 16 A minimum of 10 000 events were counted. To calculate the total CD34 + cells, the number of MNC per leukapheresis product was multiplied by the percentage of CD34 + cells.
Statistics
Statistical analysis was performed using WinSTAT software (Kalmia, USA). For comparison of the two different G-CSF groups the independent t-test was used. The cor- relation analysis was calculated by Pearson test. A P value Ͻ0.05 was considered significant.
Results

Tolerance of G-CSF
In both groups cytokine priming as well as collection of peripheral blood stem cells (PBSC), were well tolerated: 35% in the 2 × 5 g group and 25% in the 1 × 10 g group had mild myalgia or bone pain, but only 15% of the patients in both groups required non-steroidal analgesics.
PBPC collection
A median of two (range, 1-4) aphereses were performed in 49 patients resulting in a median CD34
+ cell count of 6.6 × 10 /kg CFU-GM (range, 0.15-47.9). The median leukocyte count before the first apheresis was 48.3/nl (range, 11.3-85.6) and correlated with the CD34 + cell yield (r = 0.33; P = 0.01). The median leukocyte count before the first apheresis was higher in the 2 × 5 g group than in the 1 × 10 g group (52.7/nl vs 41.9/l) resulting in a significantly higher CD34
+ cell count in the first apheresis (5.8 vs 1.9 × 10 6 /kg, P = 0.003) (Figure 1 ). Additionally the median CFU-GM (Figure 2 ) and the median MNC were significantly higher in the 2 × 5 g/kg than in the 1 × 10 g/kg group (6.5 vs 1.3 × 10 4 /kg, P = 0.002 and 6.6 vs 2.6 × 10 8 /kg, P Ͻ 0.001). Also the median BFU-E was higher in the 2 × 5 g than in the 1 × 10 g group (9.2 vs 3.1 × 10 4 /kg, P = 0.01). The target of collecting Ͼ2.5 × 10 6
CD34
+ cells was achieved in 21/27 (80%) patients in the 1 × 10 g group and in 21/22 (95%) patients in the 2 × 5 g/kg group. None in the 10 g/kg group, but 6/22 (28%) patients in the 2 × 5 g/kg group required only one apheresis procedure, resulting in fewer aphereses procedures in the 2 × 5 g/kg group (mean: 1.8 vs 2.3, P = 0.01).
Engraftment kinetics
In general, all collected CD34 + cells were reinfused. One patient with 57.3 × 10 6 /kg collected CD34 + cells received 30 × 10 6 /kg CD34 + cells. All patients engrafted with leukocyte counts Ͼ1.0/nl after a median of 10 days (range, [8] [9] [10] [11] [12] [13] [14] [15] and platelet counts Ͼ50/nl after a median of 12 days (range, 5-41). There was no difference in leukocyte and platelet engraftment between the two different schedules (10 vs 10 days, and 12 vs 13 days). The hematopoietic engraftment correlated significantly with the number of reinfused CD34
+ cells (P Ͻ 0.001), the reinfused CFU-GM (P = 0.014) and BFU-E (P = 0.002), but not with reinfused MNC. A threshold of Ͼ2.5 × 10 6 /kg CD34 + reinfused leads to a rapid platelet engraftment within 16 days, while less than 2.5 × 10 6 /kg reinfused CD34 + cells resulted in delayed platelet engraftment (Ͼ50/nl) up to 41 days (median 17 days, P = 0.12). Only seven patients had less than 2.5 × 10 6 CD34 + cells collected after three aphereses (n = 6: 1 × 10 g/kg group and n = 1: 2 × 5 g/kg group).
Discussion
Several studies have shown that the infusion of mobilized PBPC resulted in earlier hematopoietic recovery than autologous bone marrow. 2, 17 Therefore PBPC transplantation is now being widely used to enhance the hematopoietic recovery after high-dose chemotherapy. Several studies of highdose chemotherapy in breast cancer demonstrated encouraging results. [18] [19] [20] However, an optimal standard mobilizing regimen for PBSC remains to be established. In breast can-cer patients several investigators have reported the ability to mobilize PBSC using different chemotherapeutic agents in combination with growth factors. 8, 11 In general, chemotherapy plus growth factors resulted in a higher yield of CD34 + cells and CFU-GM than G-CSF alone, 21 but the chemotherapy plus G-CSF mobilized PBSC contain a smaller proportion of early progenitor cells. 22 A sufficient number of PBSC has been found to be an important predictor of engraftment regardless of the technique of mobilisation. 5, 23 There are several disadvantages of chemotherapy mobilization, including the length of time required, toxicity, febrile neutropenia and optimal timing of apheresis. In our study we could demonstrate, in a homogenous population of 49 patients with high-risk breast cancer and nearly identical pretreatment features, that mobilization with 10 g/kg G-CSF resulted in a median of 6.6 × 10 6 /kg CD34 + cells and a rapid hematopoietic recovery of leukocyte and platelets after a median of 10 and 12 days in all patients. Despite the homogenous group of breast cancer patients with nearly identical pretreatment a substantial variation in response to G-CSF was observed. In accordance with other investigators 1,4,24 the number of reinfused CD34 + cells and reinfused CFU-GM/BFU-E correlated with hematopoietic recovery. The WBC prior to first apheresis correlates in our study with CD34
+ cell harvest (r = 0.3, P = 0.01). In a previous study, we have shown a dose-dependent effect of G-CSF stimulation on the number of mobilized progenitor cells in patients with malignant lymphoma and testicular cancer.
14 In stage IV breast cancer patients this dose-response effect for priming PBPC has been confirmed comparing different doses of G-CSF (5 g/kg and 10 g/kg daily). 13, 25 Both studies reported a higher MNC yield and fewer apheresis procedures in the 10 g/kg group. Another study increased the G-CSF dose from 10 g/kg up to 40 g/kg and demonstrated a dose-response in terms of CD34 + cell harvest for the higher dose. 23 To our knowledge no data are available so far concerning a schedule dependency of G-CSF on priming PBSC. The pharmacological profile of G-CSF in healthy donors and cancer patients shows a maximum serum concentration after subcutaneous application within 2-8 h. 26 Due to the short elimination half-time of G-CSF (Filgrastim) of only about 3 to 4 h regardless of the route of administration we considered the application of G-CSF once daily might be suboptimal. Therefore we investigated the efficacy in priming PBSC with the twice 5 g/kg daily schedule and compared it with the historical once 10 g/kg daily schedule. Although the present study was not a prospective randomized trial, all patients had an identical diagnosis, nearly identical pretreatment, the same high-dose chemotherapy (CTM) and both groups were comparable with respect to age and disease status. In the 2 × 5 g/kg group there was an almost twofold higher progenitor cell yield for CD34 + cell, CFU-GM and MNC in the first apheresis. The higher CD34 + cell yield of the 2 × 5 g/kg group resulted in fewer apheresis procedures compared to the 1 × 10 g group (P = 0.008). Despite the fewer apheresis procedures the overall numbers of CFU-GM and BFU-E of all aphereses products were higher in the 2 × 5 g/kg group. Another possible explanation for improved collection of the split dose might be the timing of G-CSF application. Kinetic studies showed that the highest CD34 + cell count is reached 6-12 h after G-CSF injection. 27 The same authors reported a decrease of CD34
+ cell count within 2 h after G-CSF application. Both groups in our study received the last G-CSF injection 1-2 h prior to the apheresis procedure. The last but one G-CSF dose was injected in the 1 × 10 g/kg group 24 h, and in the 2 × 5 g/kg group 12 h prior to the apheresis procedure. Whilst no kinetic studies of CD34 + cells were performed, the higher number of MNC, CFU-GM and BFU-E of the divided dose suggest a mechanism other than timing of G-CSF. The methods of CD34
+ cell counting and culturing BFU-E and CFU-GM has not been changed during this sequential study. A threshold of 2.5 × 10 6 /kg reinfused CD34
+ cells could be shown for rapid platelet engraftment within 16 days. Only seven of the 49 patients had less than 2.5 × 10 6 /kg CD34 + cells resulting in delayed platelet engraftment (17 vs 12 days, P = 0.12). It is of note that six of those patients belonged to the 1 × 10 g/kg, whereas only one patient belonged to the 2 × 5 g group.
In summary, this study indicates that priming with 10 g/kg G-CSF alone in breast cancer patients is safe, well tolerated and effective in mobilizing PBSC. Administering G-CSF as two 5 g/kg doses daily is recommended, leading to a higher CD34
+ cell yield and requiring fewer aphereses procedures. Reinfusion of at least 2.5 × 10 6 /kg CD34 + cells after high-dose CTM chemotherapy ensures rapid hematological reconstitution.
